Navigation Links
Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
Date:6/1/2009

s two through five of treatment), the study demonstrated a strong trend in favor of XERECEPT(R), though it did not reach statistical significance (p=0.1). Placebo patients tolerated a 50 percent reduction in dexamethasone dosing much better than anticipated over this time frame.

However, at weeks two, five, and eight, the XERECEPT(R) treatment group demonstrated an improved overall response rate based on the primary endpoint that was statistically significant at each time point. XERECEPT(R) demonstrated a highly statistically significant (p=0.001) improvement compared to placebo over the twelve weeks of study duration in reducing dexamethasone dose levels. Fifteen percent of patients on XERECEPT(R) were able to reach 0 mg of dexamethasone (p= 0.04) within the twelve week period.

Approximately 20 percent of the patients enrolled in NTI-0303 had metastatic brain tumors (secondary to primary tumors in the breast, lung or elsewhere). In this patient population, the primary and all secondary endpoints achieved a statistically significant advantage for XERECEPT(R) treated patients, exceeding the results observed in the overall patient cohort. This is an important finding given the 360,000 patients diagnosed annually with metastatic brain tumors in North America and Europe; moreover, patient prognosis is very poor and the treatment options are very limited.

In addition, the NTI-0303 trial showed that use of XERECEPT(R) leads to statistically significant reductions in steroid-related adverse events of myopathy (muscle weakness) and Cushingoid syndrome. Specifically, patients demonstrated a statistically significant increase in Ileopsoas muscle strength. These findings show a medically important clinical benefit for patients on XERECEPT(R).

NTI-0501

Results from NTI-0501, a Phase III open label extension study of patients rolling over from the 0302 and 0303 studies, demonstrated the
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
2. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
3. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
4. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
5. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
8. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
9. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
10. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
11. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, ... the American Association of Tissue Banks (AATB), it ... Chief Executive Officer. Accreditation follows an ... a specially trained AATB inspector.  It establishes that ... within the facility meets or exceeds the standards ...
(Date:9/30/2014)...  Proteomics is a focus point for investment ... Kalorama Information.  The healthcare market research publisher said that ... the past two years.  The activity ranges from ... companies and academic institutions, to deals between pharma ... Kalorama observed the industry in its report, ...
(Date:9/30/2014)... -- In a recent study it was ... the Eldor spinal needle 25G, 103 mm appeared significantly ... spinal needles of the same gauge and length of ... an excellent type of regional anesthesia for many operations ... It is estimated that 100 million patients worldwide ...
Breaking Medicine Technology:Biostructures, LLC Earns AATB Accreditation 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3
...  Results from the combined analysis of two European ... 3rd European Lung Cancer Conference in Geneva, Switzerland. ... samples from advanced non-squamous non-small cell lung cancer ... plus erlotinib.  Results showed that the VeriStrat test ...
... (NASDAQ: STAA ), the leading developer, manufacturer and ... that the total number of its Visian® ICL implants in ... have been the Visian Toric ICL which is approved in ... of the U.S. The Company will highlight the benefits of ...
Cached Medicine Technology:VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer 2VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer 3STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 2STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 3STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 4STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress 5
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set ... Nashville, Tennessee. RMS welcomes the launch of an entirely ... of a new treatment center for the Lung Institute. ... Institute to Nashville, the hope is to bring awareness ... diagnosed and undiagnosed. With Nashville being a hub for ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Two revolutionary procedures ... treatment of gum disease a far less painful ... past. , “If you’ve ever felt electric shock waves surge ... sip a cold beverage, it’s possible you already know the ... who is a general dentist in West Palm Beach, and ...
(Date:9/30/2014)... (Sept. 30, 2014) Levothyroxine is considered the gold ... a new review of therapies for the condition ... altered that assessment, say a team of investigators.,1Their analysis, ... Thyroid , finds insufficient consistent data exist to ... generic, or sold under various trade names, such as ...
(Date:9/30/2014)... ANN ARBORThe discovery of a gene mutation that causes ... development of drugs that block the rapid, unstoppable cell ... at the University of Michigan and the U-M Health ... devastating disease dyskeratosis congenita, in which precious hematopoietic stem ... DC age prematurely and are prone to cancer and ...
(Date:9/30/2014)... Cleveland, Ohio (PRWEB) September 30, 2014 ... agreement which provides CHL access to Life Length’s proprietary ... most advanced and comprehensive telomere test on the market ... that reports the percentage of short telomeres, providing the ... Shay, Vice Chairman of the Department of Cell Biology ...
Breaking Medicine News(10 mins):Health News:Regenerative Medicine Solutions Expanding 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 2Health News:Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America 3
... for treating age-related loss of strength, researchers say , ... exercised and received the growth hormone known as "mechano ... to a British study. , The results suggest that ... which causes increased fragility, said Dr. Geoff Goldspink of ...
... of psychiatric side effects, including suicidal thoughts, , WEDNESDAY, ... help people quit smoking, Chantix and Zyban, will now ... problems, including depression and suicidal thoughts, U.S. health officials ... Administration said it was mandating the black-box warnings, the ...
... ... of the journal Nature includes three companion papers describing the results of ... psychiatric disorder that affects up to 70 million people worldwide. The causes ... some individuals the current treatments work well. There are multiple factors that ...
... 1 Despite rapid advances using a child,s own cord ... due to injury or disease, most pregnant women today don,t ... According to research published in the Journal of Reproductive ... themselves only "minimally informed." , , (Logo: ...
... , OAKBROOK TERRACE, Ill., July 1 Dental Network ... its acquisition of DenteMax, an independent subsidiary of Blue ... providing and administering health benefits to members residing in ... reside outside the state. , , ...
... Give BCBSM Customers Expanded National Dental Network; Solidify BCBSM Position ... Mich., July 1 Blue Cross Blue Shield of Michigan ... been acquired by Dental Network of America, LLC (DNoA), a ... BCBSM and DNoA -- will provide BCBSM with a more ...
Cached Medicine News:Health News:Growth Hormone May Build Muscle in Older Men 2Health News:Anti-Smoking Drugs Get FDA 'Black-Box' Warning 2Health News:Anti-Smoking Drugs Get FDA 'Black-Box' Warning 3Health News:International Collaboration led by Dr. Pablo V. Gejman,Researcher At NorthShore University HealthSystem's Research Institute, Finds Genetic Association of Schizophrenia to Chromosome 6p Variant 2Health News:International Collaboration led by Dr. Pablo V. Gejman,Researcher At NorthShore University HealthSystem's Research Institute, Finds Genetic Association of Schizophrenia to Chromosome 6p Variant 3Health News:International Collaboration led by Dr. Pablo V. Gejman,Researcher At NorthShore University HealthSystem's Research Institute, Finds Genetic Association of Schizophrenia to Chromosome 6p Variant 4Health News:Cord Blood Awareness Month: Understanding Still Low, Despite Medical Advancements 2Health News:Cord Blood Awareness Month: Understanding Still Low, Despite Medical Advancements 3Health News:Cord Blood Awareness Month: Understanding Still Low, Despite Medical Advancements 4Health News:Dental Network of America (DNoA) Acquires DenteMax, Owned by Blue Cross Blue Shield of Michigan 2Health News:Dental Network of America (DNoA) Acquires DenteMax, Owned by Blue Cross Blue Shield of Michigan 3Health News:Dental Network of America (DNoA) Acquires DenteMax, Owned by Blue Cross Blue Shield of Michigan 4Health News:Blue Cross Blue Shield of Michigan-owned DenteMax Acquired by Dental Network of America 2Health News:Blue Cross Blue Shield of Michigan-owned DenteMax Acquired by Dental Network of America 3Health News:Blue Cross Blue Shield of Michigan-owned DenteMax Acquired by Dental Network of America 4Health News:Blue Cross Blue Shield of Michigan-owned DenteMax Acquired by Dental Network of America 5
Used for traversing and exploring urethral strictures. The malleable tip can be shaped to desired configuration. The proximal end is threaded to attach to standard followers. Supplied sterile in peel...
Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
The balloon catheter is designed to pass over a previously placed .015 inch diameter wire guide included. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Medicine Products: